CTKB Cytek Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTKB

Price (delayed)

$4.315

Market cap

$557.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.57

Enterprise value

$505.41M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 45
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 19
Highlights
The company's revenue rose by 3.6% YoY
The debt has soared by 65% YoY but it has contracted by 5% from the previous quarter
The quick ratio has contracted by 18% YoY and by 7% from the previous quarter
Cytek Biosciences's equity has decreased by 14% YoY and by 4.1% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: https://www.cytekdev.com/
Peers: OBIO OM

Key stats

What are the main financial stats of CTKB

CTKB stock price

How has the Cytek Biosciences stock price performed over time
Intraday
6.54%
1 week
4.73%
1 month
-7.4%
1 year
26.91%
YTD
-14.55%
QTD
-1.26%

Financial performance

How have Cytek Biosciences's revenue and profit performed over time
Revenue
$204.17M
Gross profit
$105.56M
Operating income
-$43.87M
Net income
-$74M
Gross margin
51.7%
Net margin
-36.2%
CTKB's operating income has plunged by 77% YoY and by 9% from the previous quarter
The operating margin has plunged by 71% YoY and by 8% from the previous quarter
The net income is down by 11% since the previous quarter
The net margin has contracted by 10% from the previous quarter

Price vs fundamentals

How does CTKB's price correlate with its fundamentals

Growth

What is Cytek Biosciences's growth rate over time

Valuation

What is Cytek Biosciences stock price valuation
CTKB P/E details
P/E
N/A
P/B
1.69
P/S
2.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.48
Cytek Biosciences's EPS has decreased by 10% from the previous quarter
CTKB's price to book (P/B) is 43% lower than its 5-year quarterly average of 2.8 but 6% higher than its last 4 quarters average of 1.5
Cytek Biosciences's equity has decreased by 14% YoY and by 4.1% from the previous quarter
The P/S is 61% below the 5-year quarterly average of 6.5
The company's revenue rose by 3.6% YoY

Efficiency

How efficient is Cytek Biosciences business performance
The return on invested capital has declined by 22% since the previous quarter
Cytek Biosciences's ROS has decreased by 19% from the previous quarter
Cytek Biosciences's return on equity has decreased by 16% QoQ
Cytek Biosciences's return on assets has decreased by 13% QoQ

Dividends

What is CTKB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTKB.

Financial health

How did Cytek Biosciences financials performed over time
The quick ratio has contracted by 18% YoY and by 7% from the previous quarter
The total liabilities has grown by 18% YoY
The debt is 96% less than the equity
The debt to equity has soared by 100% YoY
The debt has soared by 65% YoY but it has contracted by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.